iBio Corp - נכסים נקיים למניה בודדת IBIO

iBio, Inc. (IBIO) is developing organic R&D, aiming for critical licenses with pharmaceutical behemoths. The book value per share, with GURU.Markets data illustrated on this chart, is rising, and the latest mark stands at 1.54. Business resilience is based on the RubrYc AI platform with closed patents, while human capital is secured by attracting top bioengineers through stock option programs.

For iBio, Inc., whose valuation relies on the intellectual property of the RubrYc platform, the current book value per share serves as an indicator of the business's material stability. This metric is calculated by dividing the total net assets by the number of shares outstanding, allowing investors to assess the company's intrinsic value and the risk of capital undervaluation relative to market quotes.